New Economy Portfolio Update..bought a stock that should have Phase 3 data soon. Traded it several times over the past 3-6 months.
Alert..bought starter of $CPRX at $3.04 in the New Economy Portfolio. I will hold this through the Phase 3 Firdapse data.
Granting options to its execs at $3.12. I think this would be a good sign ahead of the Firdapse data. My thoughts & opinion on this of which I could be wrong.
Item 8.01 Other Events Stock Option Grants
On August 28, 2014, the Compensation Committee of the Company’s Board of Directors (the “Committee”) granted seven-year stock options to purchase an aggregate of 1,210,000 shares of the Company’s authorized but unissued common stock to various current officers, directors and employees of the Company. These stock options were granted under the Company’s 2014 Stock Incentive Plan and have an exercise price of $3.12 per share (the closing price of the Company’s common stock on such date on the NASDAQ Capital Market).
Because the Company did not have sufficient shares of common stock available for grant under its 2006 Stock Incentive Plan at the end of 2013, no option grants were made to the current officers, directors and employees of the Company (consistent with the Company’s historic compensation practices) for 2013 services. With the approval by the Company’s stockholders at the 2014 annual stockholders’ meeting of the 2014 Stock Incentive Plan, the Company again has shares of common stock available for grant to Company officers, directors and employees as part of the compensation for their services. The stock option grants made by the Committee on August 28, 2014 are intended to compensate the Company’s current officers, directors and employees for their services during 2013. Initiation of Phase 1(b) clinical trial of CPP-115 On September 2, 2014, the Company issued a press release announcing the initiation of its second Phase 1 safety and tolerance study for CPP-115, a novel GABA aminotransferase (GABA-AT) inhibitor. The Phase 1(b) trial is designed in two parts to evaluate the safety and tolerability of single and multiple doses of CPP-115, including CNS side effects, and respiratory and cardiovascular safety. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. http://ih.advfn.com/p.php?pid=nmona&article=63449364
News 
Market Data 
Discover 
